When was Elicio founded?

Elicio was founded in 2012 and raised its 1st funding round within a year of its incorporation.

Where is Elicio located?

Elicio is headquartered in Cambridge, United States.

How many employees does Elicio have?

As of May 31, 2026, the latest employee count at Elicio is 46.

Is Elicio a funded company?

Elicio is a funded company, having raised a total of $47.4M across 11 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 07, 2012.

When was the latest funding round of Elicio?

Elicio's latest funding was a $***** Post IPO round on Dec 22, 2023, with participation from 0 investor.

Where does Elicio rank among its competitors?

Elicio ranks 14th amongst 3226 active competitors, of which 1112 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Elicio?

Elicio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Elicio - 2026 Company Profile, Team, Funding, Competitors & Financials

Elicio is a public company based in Cambridge (United States), founded in 2012 by Darrell Irvine. It operates as a Developer of vaccines for treating cancer. Elicio has raised $47.4M in funding. The company has 3226 active competitors, including 1112 funded and 764 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of vaccines for treating cancer. The company has developed lymph node targeted cell therapy activators, immunomodulators, and vaccines using the Amphiphile platform to control the immune signals and activate the immune system against cancer.

Website: elicio.com
Email ID: *****@elicio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2012

Location

Cambridge, United States

Stage

Public

Total Funding

$47.4M in 11 rounds

Latest Funding Round

Post IPO, Dec 22, 2023, $*****

Investors

Dreavent & 6 more

Ranked

14^th among 3226 active competitors

Employee Count

46 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2967 more

Exit Details

Public

View Elicio's full profile

Elicio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VEDANTRA PHARMACEUTICALS, INC. CIN: 0001555192 , United States, Active		-	5 (As on Dec 31, 2017)	-
Elicio Therapeutics, Inc. CIN: 1601485 , United States, Active		-	-	-

Elicio got listed on Feb 05, 2021.

Click here to take a look at Elicio's IPO in detail

Elicio has raised a total funding of $47.4M over 11 rounds. Its first funding round was on May 07, 2012. Elicio has 7 institutional investors.

Here is the list of recent funding rounds of Elicio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 22, 2023	5857522	Post IPO	5480681	8421986	6750400	2357512
Sep 07, 2023	2565169	Grant (prize money)	9891680	6319711	7120863	Giresearchfoundation
Nov 02, 2022	3454960	Post IPO	7558017	4952458	5128702	2950893

Access funding benchmarks and valuations. Sign up today!

View details of Elicio's funding rounds and investors

The founders of Elicio is Darrell Irvine. Robert Connelly is the CEO of Elicio.

Here are the details of Elicio's key team members:

Darrell Irvine: Founder of Elicio and founder of 2 other companies, Ankyra and Strand Therapeutics.
Contact Info: 1 email address
Robert Connelly: CEO of Elicio.

View details of Elicio's Founder profiles and Board Members

Elicio's employee count trend

Elicio has 46 employees as of May 26. Here is Elicio's employee count trend over the years:

Uncover Elicio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Elicio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Elicio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
14th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100